In 2024 and into 2025, families of trans young people who had been receiving gender-affirming care through the NHS WellBN service in Brighton received letters instructing them to stop hormone treatment. For many of those young people, this was not a clinical recommendation based on their individual circumstances. It was an administrative consequence of the political and regulatory environment that followed the Cass Review and the subsequent restrictions on puberty blockers and gender-affirming hormones for under-18s. Families described it, accurately, as forced detransition. I want to explain what happened, what the legal picture looks like, and what families can actually do.
What happened at the WellBN centre?
WellBN, based in Brighton, was one of the NHS services providing some gender-related care to young people in its area. When NHS England moved to restrict access to puberty blockers and gender-affirming hormones for under-18s following the Cass Review, services like WellBN were caught in the same sweep. Clinicians who had been managing young people's care found themselves unable to continue prescribing under NHS rules, regardless of how long those young people had been on treatment, how well they were doing, or what the clinical picture looked like for each individual.
The letters families received did not say "we have reviewed your child's care and concluded treatment should stop." They said, in effect, that the treatment could no longer be provided. That is a crucial distinction. A clinical decision based on an individual assessment is one thing. An administrative withdrawal of treatment based on a blanket policy is another, and the legal exposure of those two scenarios is very different.
Why the Cass Review matters here
The Cass Review, published in April 2024, recommended against routine prescribing of puberty blockers and gender-affirming hormones to under-18s outside a research context. NHS England moved quickly to implement restrictions, and those restrictions have remained in place. The Review has been the subject of significant international criticism. Many gender specialists, clinicians, and researchers have published detailed challenges to its methodology and its conclusions. The review's citation patterns and its selective use of evidence have been called into question by experts across several countries, and major international bodies have not adopted its recommendations.
None of that criticism has yet changed UK policy. The restrictions remain, and families are living with the consequences. What the criticism does mean, legally and practically, is that the policy rests on contested ground, and that contestability matters when you are trying to challenge an administrative decision about your child's care.
Is this lawful? The legal analysis
This is the question families are asking, and the answer is genuinely contested territory. There are several legal angles worth understanding.
The duty of individual clinical assessment
NHS bodies have a legal duty to make clinical decisions based on individual circumstances, not solely on blanket policy. The courts have long held that a decision-maker must not fetter its own discretion, meaning it cannot simply say "our policy says no" without considering whether the policy applies appropriately to the individual in front of it. If a young person was established on treatment, was doing well, and had a clinical team that supported continuation, a letter stopping that treatment without individual review raises real questions about whether the NHS met that duty.
The Equality Act 2010
Trans young people are protected under the Equality Act 2010 through the characteristic of gender reassignment. A policy that removes treatment from trans young people wholesale, without individual consideration, may amount to indirect discrimination, or even direct discrimination, depending on how it was implemented. Families may have grounds to argue that the way the withdrawal was carried out failed to make reasonable adjustments or treated their child less favourably because of a protected characteristic.
The Human Rights Act 1998
Article 8 of the European Convention on Human Rights, incorporated into UK law through the Human Rights Act 1998, protects the right to private and family life, which includes a person's physical and psychological integrity and their right to make decisions about their own body and identity. An abrupt, policy-driven withdrawal of ongoing treatment, particularly one that causes measurable harm through the return of unwanted puberty changes, distress, or psychological deterioration, is at least arguable as an interference with that right. Article 3, the prohibition of inhuman or degrading treatment, may also be relevant in the most severe cases, though this is a higher bar.
The common law duty of care
A clinician who has an established therapeutic relationship with a patient cannot simply withdraw from that relationship without proper handover and without acting in the patient's best interests. If a young person's treatment was stopped abruptly and no safe alternative was offered, that raises questions about whether the duty of care was properly discharged, both by the individual clinician and by the NHS body responsible for the service.
Gillick competence and the child's own rights
Where a young person is Gillick competent, meaning they have sufficient understanding and maturity to consent to treatment for themselves, their own legal rights in relation to their care are engaged. A competent young person's right to make decisions about their treatment is not simply overridden by a parental or policy decision. If the young person themselves consented to treatment and wished it to continue, that matters legally and ethically.
What about the research pathway?
NHS England stated that gender-affirming treatment for under-18s could continue in a research context. In practice, that research pathway has not been accessible to most families. The infrastructure has not been built quickly enough, the criteria have been narrow, and many young people who were mid-treatment simply could not access it. A research pathway that exists in name but not in practice is not a meaningful alternative, and the gap between the stated policy and the lived reality is itself relevant to any legal challenge.
What can families do right now?
If your child received one of these letters, or if their treatment has already been stopped, there are several concrete steps worth taking.
First, request the full clinical record and the written basis for the decision to stop treatment. Ask specifically whether an individual clinical assessment was carried out, or whether the decision was made solely on the basis of NHS England's policy. The answer to that question shapes everything else.
Second, make a formal complaint to the NHS trust responsible for the service, and to NHS England directly. Document the impact on your child: any return of unwanted physical changes, any deterioration in mental health, any distress. This documentation matters both for the complaint and for any subsequent legal action.
Third, consider contacting a solicitor with experience in healthcare law or public law judicial review. The legal arguments outlined above are not guaranteed to succeed, but they are real arguments, and some families are already pursuing them. A solicitor can advise on the specific facts of your child's case and on whether judicial review or a complaint to the Parliamentary and Health Service Ombudsman is the right route.
Fourth, look at whether private care is accessible to you. I know that is not an option for every family, and I am not saying it should have to be. But where a young person's treatment has been stopped and they are deteriorating, the immediate clinical priority is getting them back on treatment safely. GenderGP at gendergp.com provides gender-affirming care using current international standards, and can be a route to continuation of treatment while a legal or NHS complaint process runs in parallel.
Fifth, connect with other families in the same position. Collective legal action carries more weight than individual complaints, and knowing you are not the only family facing this can matter enormously to young people who are already dealing with a great deal.
The harm of stopping treatment mid-transition
The policy conversation often abstracts this, so I want to be direct. When a young person who has been on puberty blockers or gender-affirming hormones has that treatment stopped abruptly, their body does not simply pause. Puberty resumes. Physical changes that the treatment was preventing or reversing can return or accelerate. For many young people, those changes are experienced as deeply distressing, sometimes acutely so. The psychological impact of having something taken away that was helping them is not a theoretical risk. It is what families are describing, and it is what the clinical literature on interrupted treatment would predict.
The framing that restricting gender-affirming treatment is a cautious, harm-minimising approach does not survive contact with what is actually happening to these young people. Withholding or stopping care is not neutral. It has consequences, and those consequences are borne by the young people, not by the policymakers.
The international picture
The UK's policy direction is not shared by the majority of countries with established gender medicine traditions. WPATH's Standards of Care 8, the Endocrine Society guidelines, and the positions of major medical bodies in the United States, Canada, Australia, and across Europe support access to gender-affirming care for young people who meet the clinical criteria. The American Academy of Child and Adolescent Psychiatry reaffirmed its support for evidence-based gender-affirming care in 2025, explicitly in response to political pressure. That international context matters when the UK government or NHS England frames its policy as following the evidence, because the evidence, as understood by the international clinical community, does not support what is happening here.
What I want families to know
If your child's treatment has been stopped and you are trying to work out what to do, I want you to know that your instinct that something is wrong here is correct. You are not misreading the situation. What happened was not a careful individual clinical decision made in your child's best interests. It was an administrative consequence of a policy that the international clinical community has largely rejected, implemented in a way that left young people and families without proper support or alternatives.
That does not mean there is an easy fix, and the legal routes are not straightforward or fast. But the arguments exist, other families are pursuing them, and the harm being caused is real and documentable. You have the right to ask hard questions of the NHS, and you have the right to seek legal advice about whether the way your child's care was stopped was lawful.
If there is a topic that you would like me to cover, just let Sammy know.
Written by Dr Helen Webberley, Gender Specialist and founder of GenderGP, writing in her capacity as an advocate and educator.